Esperion Therapeutics, Inc. (ESPR)
USD 1.09
(10.77%)
USD 1.09
(10.77%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 458.69 Million USD | 236.85% |
| 2022 | 136.17 Million USD | 165.42% |
| 2021 | 51.3 Million USD | 142.91% |
| 2020 | -119.55 Million USD | 27.35% |
| 2019 | -164.56 Million USD | -345.1% |
| 2018 | -36.97 Million USD | -10.62% |
| 2017 | -33.42 Million USD | 5.68% |
| 2016 | -35.43 Million USD | 51.49% |
| 2015 | -73.04 Million USD | 8.81% |
| 2014 | -80.1 Million USD | -41.68% |
| 2013 | -56.53 Million USD | -447.74% |
| 2012 | 16.25 Million USD | 205.25% |
| 2011 | 5.32 Million USD | 0.0% |
| 2002 | -31.7 Million USD | 50.41% |
| 2001 | -63.94 Million USD | 3.85% |
| 2000 | -66.5 Million USD | -2028.36% |
| 1999 | -3.12 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 367.33 Million USD | 13.98% |
| 2024 Q1 | 322.26 Million USD | -29.74% |
| 2023 Q3 | 149.29 Million USD | 19.77% |
| 2023 FY | 458.69 Million USD | 236.85% |
| 2023 Q1 | 116.49 Million USD | -14.45% |
| 2023 Q4 | 458.69 Million USD | 207.24% |
| 2023 Q2 | 124.65 Million USD | 7.01% |
| 2022 Q1 | 109.79 Million USD | 114.01% |
| 2022 FY | 136.17 Million USD | 165.42% |
| 2022 Q2 | 137.23 Million USD | 24.99% |
| 2022 Q3 | 100.82 Million USD | -26.53% |
| 2022 Q4 | 136.17 Million USD | 35.05% |
| 2021 Q3 | 172.55 Million USD | 201.78% |
| 2021 Q4 | 51.3 Million USD | -70.27% |
| 2021 Q2 | 57.17 Million USD | -2.45% |
| 2021 FY | 51.3 Million USD | 142.91% |
| 2021 Q1 | 58.61 Million USD | 149.03% |
| 2020 Q2 | -292.29 Million USD | -103.33% |
| 2020 Q1 | -143.75 Million USD | 12.65% |
| 2020 Q3 | -209.01 Million USD | 28.49% |
| 2020 Q4 | -119.55 Million USD | 42.8% |
| 2020 FY | -119.55 Million USD | 27.35% |
| 2019 FY | -164.56 Million USD | -345.1% |
| 2019 Q2 | -273.38 Million USD | -57.24% |
| 2019 Q4 | -164.56 Million USD | 21.97% |
| 2019 Q3 | -210.89 Million USD | 22.86% |
| 2019 Q1 | -173.86 Million USD | -370.24% |
| 2018 Q4 | -36.97 Million USD | -38.19% |
| 2018 FY | -36.97 Million USD | -10.62% |
| 2018 Q3 | -26.75 Million USD | -10.43% |
| 2018 Q2 | -24.22 Million USD | 19.83% |
| 2018 Q1 | -30.22 Million USD | 9.58% |
| 2017 Q2 | -18.46 Million USD | -5.27% |
| 2017 FY | -33.42 Million USD | 5.68% |
| 2017 Q4 | -33.42 Million USD | -71.01% |
| 2017 Q3 | -19.54 Million USD | -5.83% |
| 2017 Q1 | -17.54 Million USD | 50.49% |
| 2016 FY | -35.43 Million USD | 51.49% |
| 2016 Q1 | -33.29 Million USD | 54.42% |
| 2016 Q2 | -45.24 Million USD | -35.88% |
| 2016 Q3 | -44 Million USD | 2.73% |
| 2016 Q4 | -35.43 Million USD | 19.48% |
| 2015 Q4 | -73.04 Million USD | 4.09% |
| 2015 FY | -73.04 Million USD | 8.81% |
| 2015 Q1 | -203.75 Million USD | -154.37% |
| 2015 Q2 | -124.88 Million USD | 38.71% |
| 2015 Q3 | -76.16 Million USD | 39.02% |
| 2014 Q4 | -80.1 Million USD | -126.9% |
| 2014 Q2 | -43.02 Million USD | 11.55% |
| 2014 FY | -80.1 Million USD | -41.68% |
| 2014 Q1 | -48.63 Million USD | 13.97% |
| 2014 Q3 | -35.3 Million USD | 17.94% |
| 2013 Q1 | -20.88 Million USD | -228.46% |
| 2013 FY | -56.53 Million USD | -447.74% |
| 2013 Q4 | -56.53 Million USD | 21.36% |
| 2013 Q3 | -71.89 Million USD | -332.41% |
| 2013 Q2 | -16.62 Million USD | 20.39% |
| 2012 FY | 16.25 Million USD | 205.25% |
| 2012 Q4 | 16.25 Million USD | 0.0% |
| 2011 FY | 5.32 Million USD | 0.0% |
| 2003 Q1 | -22.8 Million USD | 28.08% |
| 2003 Q2 | -19.15 Million USD | 15.99% |
| 2003 Q3 | -55.55 Million USD | -190.03% |
| 2002 Q3 | -33.19 Million USD | 10.99% |
| 2002 Q2 | -37.28 Million USD | 33.34% |
| 2002 Q4 | -31.7 Million USD | 4.47% |
| 2002 FY | -31.7 Million USD | 50.41% |
| 2002 Q1 | -55.93 Million USD | 12.52% |
| 2001 Q1 | -60.65 Million USD | 8.79% |
| 2001 Q2 | -47.48 Million USD | 21.72% |
| 2001 Q3 | -70.64 Million USD | -48.79% |
| 2001 Q4 | -63.94 Million USD | 9.49% |
| 2001 FY | -63.94 Million USD | 3.85% |
| 2000 Q3 | -72.66 Million USD | -259.44% |
| 2000 Q1 | -25.07 Million USD | 0.0% |
| 2000 FY | -66.5 Million USD | -2028.36% |
| 2000 Q2 | -20.21 Million USD | 19.4% |
| 2000 Q4 | -66.5 Million USD | 8.47% |
| 1999 FY | -3.12 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 94.2 Million USD | -386.905% |
| Aquestive Therapeutics, Inc. | 74.95 Million USD | -512.007% |
| Collegium Pharmaceutical, Inc. | 435.33 Million USD | -5.367% |
| Cosmos Health Inc. | 8.59 Million USD | -5239.448% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 5684.712% |
| Cronos Group Inc. | -663.32 Million USD | 169.151% |
| Incannex Healthcare Limited | -5.48 Million USD | 8462.789% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 3247.811% |
| Lifecore Biomedical, Inc. | 121.89 Million USD | -276.297% |
| Regencell Bioscience Holdings Limited | -2.9 Million USD | 15909.422% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 3033.863% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 3033.863% |
| SCYNEXIS, Inc. | -19.35 Million USD | 2470.537% |
| Safety Shot Inc | -2.28 Million USD | 20179.847% |
| Theratechnologies Inc. | 24.87 Million USD | -1744.313% |
| Alpha Teknova, Inc. | 1.97 Million USD | -23137.031% |
| Universe Pharmaceuticals INC | 197.2 Thousand USD | -232495.368% |
| Pacira BioSciences, Inc. | 432.74 Million USD | -5.997% |
| Sonoma Pharmaceuticals, Inc. | -2.52 Million USD | 18302.341% |
| Dynavax Technologies Corporation | 106.63 Million USD | -330.158% |
| Ironwood Pharmaceuticals, Inc. | 623.38 Million USD | 26.418% |
| Radius Health, Inc. | 359.28 Million USD | -27.671% |
| China SXT Pharmaceuticals, Inc. | -9.42 Million USD | 4964.391% |
| Alvotech | 1.06 Billion USD | 56.902% |
| Intra-Cellular Therapies, Inc. | -130.82 Million USD | 450.61% |
| SIGA Technologies, Inc. | -148.68 Million USD | 408.51% |
| Shineco, Inc. | 29.29 Million USD | -1466.044% |
| Silver Spike Investment Corp. | -32.61 Million USD | 1506.55% |
| Journey Medical Corporation | -9.7 Million USD | 4824.472% |
| Petros Pharmaceuticals, Inc. | -5.06 Million USD | 9164.51% |
| Embecta Corp. | 1.31 Billion USD | 65.038% |
| Harrow Health, Inc. | 116.41 Million USD | -294.014% |
| Procaps Group, S.A. | 242.93 Million USD | -88.818% |
| Biofrontera Inc. | 4.05 Million USD | -11209.147% |
| DURECT Corporation | -7.65 Million USD | 6092.932% |
| PainReform Ltd. | -7.95 Million USD | 5869.799% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 1468.148% |
| OptiNose, Inc. | 58.06 Million USD | -689.975% |
| RedHill Biopharma Ltd. | -5.18 Million USD | 8944.895% |
| Organogenesis Holdings Inc. | 15.01 Million USD | -2955.345% |
| Cumberland Pharmaceuticals Inc. | 106.85 Thousand USD | -429156.31% |
| ProPhase Labs, Inc. | 19.23 Million USD | -2285.206% |
| Phibro Animal Health Corporation | 454.84 Million USD | -0.847% |
| Procaps Group S.A. | 242.93 Million USD | -88.818% |
| TherapeuticsMD, Inc. | 3.67 Million USD | -12371.425% |
| Viatris Inc. | 17.13 Billion USD | 97.322% |
| Rockwell Medical, Inc. | 4.45 Million USD | -10193.963% |
| Aytu BioPharma, Inc. | -4.87 Million USD | 9505.352% |
| Tilray Brands, Inc. | 158.97 Million USD | -188.532% |
| PetIQ, Inc. | 351.93 Million USD | -30.337% |
| Talphera, Inc. | -5.72 Million USD | 8117.812% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | -158.713% |
| Alimera Sciences, Inc. | 55.3 Million USD | -729.339% |
| Assertio Holdings, Inc. | -32.52 Million USD | 1510.123% |
| Shuttle Pharmaceuticals Holdings, Inc. | -1.48 Million USD | 30911.595% |
| Avadel Pharmaceuticals plc | 4.21 Million USD | -10777.377% |
| Hempacco Co., Inc. | 13.61 Million USD | -3269.15% |
| Alvotech | 1.06 Billion USD | 56.902% |
| Lantheus Holdings, Inc. | -96.71 Million USD | 574.304% |
| Kamada Ltd. | -46.43 Million USD | 1087.904% |
| Currenc Group, Inc. | -16.57 Million USD | 2867.728% |
| Indivior PLC | -33.95 Million USD | 1451.022% |
| Evoke Pharma, Inc. | 260.57 Thousand USD | -175934.063% |
| Flora Growth Corp. | -713 Thousand USD | 64433.661% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 5684.712% |
| Evolus, Inc. | 63.7 Million USD | -620.002% |
| HUTCHMED (China) Limited | -197.45 Million USD | 332.302% |
| Amphastar Pharmaceuticals, Inc. | 479.11 Million USD | 4.26% |
| Akanda Corp. | 3.9 Million USD | -11646.706% |